NCT02432313View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Pharmacokinetics of Anatabine
Interventions
DRUG

Modified Release Formulation x (MRx)

Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation

Trial Locations (1)

NG11 6JS

Quotient Clinical, Nottingham

All Listed Sponsors
lead

Rock Creek Pharmaceuticals, Inc.

INDUSTRY

NCT02432313 - Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations | Biotech Hunter | Biotech Hunter